Panel Hero

COVID-19 Therapeutics Information Page

Panel Notice

Notice

  • As of 9/16/21, the Emergency Use Authorization's for both monoclonal antibody therapies (bamlanivimab + etesevimab and REGEN-COV) have been expanded to include post-exposure prophylaxis for individuals who are at high risk for progression to severe COVID-19.